

A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors

NCT06541002

Status	RECRUITING
Phase	Not Applicable
Sponsor	Massachusetts General Hospital
Enrollment	300 participants

Key Eligibility Criteria

Inclusion (2)

- Adult patients (> 18 years) who underwent autologous or allogeneic HCT > three months prior to study enrollment
- Screen positive for sexual health concerns causing distress based on the National Comprehensive Network (NCCN) survivorship guidelines screening questions

Exclusion (3)

- Patients who do not comprehend English or Spanish since SHIFT will only be available in these two languages for this efficacy trial.
- Patients with any major uncontrolled psychiatric disorder or other comorbid cognitive conditions, which the treating HCT clinician believes would prohibit the patients' capacity to provide informed consent and participate in study procedures.
- Patients with relapsed disease requiring treatment.

Locations (3 total)

University of Miami, Coral Gables, Florida, United States
Massachusetts General Hospital (MGH), Boston, Massachusetts, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States